Clinical Trial

A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Randomized, Open-Label, Parallel-Controlled, Multicenter Phase III Clinical Trial to Evaluate the Safety and Efficacy of Anlotinib Hydrochloride Combined with Benmelstobart versus Toripalimab Combined with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma Harboring Specific Gene Mutations
Trial Details
NCT Number NCT07446335
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Conditions Advanced Esophageal Squamous Cell Carcinoma
Enrollment 578 participants
Start Date 2026-04
Primary Completion 2028-12 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-03